To determine the efficacy of ibrutinib in p53-mutant CLL, cohorts of Eμ-TCL1;p53R172H and Eμ-TCL1 mice were treated daily with 25 mg/kg of ibrutinib via oral gavage beginning at 8 months of age. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.